- Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, making it one of the very few peptides here with an approved indication studied directly in women.
- PT-141's approval covers premenopausal women specifically; its efficacy in postmenopausal women was not established, so even the female-approved compound has clear evidence boundaries.
- The other compounds discussed around sexual wellness, including kisspeptin-10, oxytocin, and melanotan-2, were not studied for female sexual desire, and melanotan-2 is an unapproved compound with documented safety concerns.
Across this database the recurring finding is absence: compounds studied in men, or in no one in particular, and then described as if the results apply to women. Sexual-wellness peptides are the rare place with a genuine counter-example. One compound in this space was developed, trialed, and approved specifically in women. That fact anchors this entire topic, and it also sets a bar the surrounding compounds do not clear.
The anchor: a peptide approved specifically in women
Bremelanotide, or PT-141, is a melanocortin-receptor agonist, marketed as Vyleesi and FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Mechanistically it acts as a non-selective agonist at melanocortin receptors, primarily MC4R, in the central nervous system, where it modulates dopaminergic pathways involved in sexual desire. What matters for this site is not the mechanism but the population: it was studied in women, so its efficacy evidence base is female-direct rather than male-extrapolated.
That boundary is the honest part. Even the compound this database can point to as female-studied has open questions: as-needed dosing was not evaluated against specific menstrual-cycle phases, and the approved indication stops at premenopausal women. Approval in women is a real distinction, and it is still not a blanket endorsement across every woman or every situation. It is also not recommended in pregnancy, and should be discontinued if pregnancy is suspected.
PT-141's approved regimen (an as-needed 1.75 mg subcutaneous dose) appears in its prescribing information and is reported here only for reference. This site does not publish personal dosing or instructions, and an approved medicine like this is used under a clinician's direction, not on the basis of a research page.
The wider context: related, but not studied for this
Around that anchor sit compounds that get pulled into sexual-wellness conversations for reasons of biology or family resemblance, not because anyone studied them for female desire. Kisspeptin-10 has genuinely been studied directly in women, but in reproductive-axis and fertility research, upstream of LH and FSH, not as a treatment for low libido. Oxytocin carries an unusually female-rich literature spanning reproduction, lactation, and social bonding, and that bonding angle is why it gets mentioned here, but its female evidence is not evidence about sexual desire as an outcome.
The most important cautionary note is melanotan-2. It is a non-selective melanocortin agonist sold illicitly as a tanning agent, and it is chemically related to bremelanotide, which is exactly why it borrows PT-141's reputation. It should not. It is not an approved drug, its early human studies focused largely on men, no female-specific analysis exists, and it is associated with documented safety concerns. The selective, female-approved relative was developed separately; the resemblance is not a transfer of evidence.
| Compound | Female-specific status for sexual wellness | Approval / safety note |
|---|---|---|
| Bremelanotide (PT-141) | Trialed and approved directly in premenopausal women for HSDD | FDA-approved (Vyleesi); postmenopausal efficacy not established |
| Kisspeptin-10 | Studied directly in women, but for reproductive-axis research, not libido | Investigational; no established therapeutic dose |
| Oxytocin | Female-rich literature, but not on sexual desire as an outcome | Approved only in obstetrics, under medical supervision |
| Melanotan-2 | Early human studies focused largely on men; no female-specific analysis | Not approved; documented safety concerns |
Why the anchor matters
PT-141 is useful precisely because it is the exception. It shows what it looks like when a compound's female claims rest on studies actually run in women, and by contrast it exposes how much of the surrounding conversation is inference and family resemblance. The lesson is not that peptides work for libido; it is that only one here was studied to that standard in women, and even it has limits printed on the label.
That is the female-evidence lens applied honestly: one direct answer, several open questions, and one compound that borrows credibility it did not earn. The full study-count and safety breakdowns are on each linked profile, starting with bremelanotide (PT-141).